Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein

the Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor Over Monotherapy on Urinary Protein in Patients With Type 2 Diabetes

The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.

This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.

Inclusion Criteria:

• Age greater than or equal to 18 years
• Clinical diagnosis of type 2 diabetes mellitus
• Immediate urine albumin creatinine ratio greater than 30mg/g
• Signed informed consent and available for follow-up

Exclusion Criteria:

• severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2
• clinical diagnosis of various acute and chronic urinary tract infections
• combined with various serious infectious diseases
• combined with acute complications of diabetes mellitus
• end-stage malignancy
• pregnancy and lactation